New Study Using Aptar's Nasal Drug Delivery System Validates Insulin Nasal Spray to Deliver Alzheimer's Drug Directly to the Brain [Yahoo! Finance]
New Study Using Aptar’s Nasal Drug Delivery System Validates Insulin Nasal Spray to Deliver Alzheimer’s Drug Directly to the Brain
AptarGroup, Inc. (NYSE: ATR) had its price target raised by analysts at Wells Fargo & Company from $170.00 to $173.00. They now have an "overweight" rating on the stock.
Aptar Pharma Bolsters Clinical Trial Capabilities with Strategic Materials Manufacturing Acquisition
AptarGroup, Inc. (NYSE: ATR) had its price target raised by analysts at Raymond James Financial, Inc. from $175.00 to $182.00. They now have an "outperform" rating on the stock.